Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar

 
• By Joseph Haas, Eleanor Malone, and Alexandra Shimmings

Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.

DealWatch_1200x675

More from Deals

More from Business